Saturday, August 30, 2014 Last update: 10:03 AM
FreshNews.com - All Company Technology News Since 1996

Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel

Companies mentioned in this article: Enanta Pharmaceuticals, Inc.

WATERTOWN, Mass. -- (BUSINESS WIRE) -- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel. Mr. Gardiner has over 25 years of experience as outside general counsel advising private and public biotechnology companies.

“After working with Nat for so many years as our outside counsel, we are thrilled to have him join as a permanent member of senior management,” commented Jay R. Luly, Ph.D.

Mr. Gardiner was previously a corporate and securities law partner for 25 years, starting at Palmer & Dodge LLP and continuing through its merger into Edwards Angell Palmer & Dodge LLP, which is now known as Edwards Wildman Palmer LLP. Since 2008 Mr. Gardiner had been co-chair of the firm’s Life Sciences Group, and before that he was co-chair of the Business Law Department. In his private practice, Mr. Gardiner was Enanta’s outside counsel and Secretary since it was founded, and he led its IPO legal team. He also serves as a Trustee of Joslin Diabetes Center, Inc. in Boston, where he is a member of the Executive Committee and Chair of the Compensation Committee.

Mr. Gardiner received his A.B. from Harvard College and his J.D. from the University of Virginia School of Law.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.


Copyright © Business Wire 2014
Contact:

Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com